AstraZeneca buys into startup RQ Bio’s COVID antibodies
Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended […]
Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended […]
The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.
The treatment could be lifesaving for many who cannot get protection from the vaccine, but confusion about the drug has made some doctors slow to […]
The treatment could be lifesaving for many who cannot get protection from the vaccine, but confusion about the drug has made some doctors slow to […]
The treatment could be lifesaving for many who cannot get protection from the vaccine, but confusion about the drug has made some doctors slow to […]
The treatment could be lifesaving for many who cannot get protection from the vaccine, but confusion about the drug has made some doctors slow to […]
The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness.
The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness.
Scarce supplies and surging Covid cases have caused health officials, hospitals, doctors and patients to scramble for pills and infusions.
Scarce supplies and surging Covid cases have caused health officials, hospitals, doctors and patients to scramble for pills and infusions.
Scarce supplies and surging Covid cases have caused health officials, hospitals, doctors and patients to scramble for pills and infusions.
Scarce supplies and surging Covid cases have caused health officials, hospitals, doctors and patients to scramble for pills and infusions.
The antibody drug, Evusheld, was found to be strongly effective in preventing Covid in a clinical trial that enrolled mostly those at high risk.
The antibody drug, Evusheld, was found to be strongly effective in preventing Covid in a clinical trial that enrolled mostly those at high risk.
The antibody drug, Evusheld, was found to be strongly effective in preventing Covid in a clinical trial that enrolled mostly those at high risk.
The treatment, known as molnupiravir, could be authorized in the United States within days, and available within weeks, if the F.D.A. follows the committee’s recommendation.
The treatment, known as molnupiravir, could be authorized in the United States within days, and available within weeks, if the F.D.A. follows the committee’s recommendation.
The treatment, known as molnupiravir, could be authorized in the United States within days, and available within weeks, if the F.D.A. follows the committee’s recommendation.
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
Pfizer’s is the second pill to show effectiveness against Covid-19, and it is the first purpose-built to attack the virus that causes the disease.
Pfizer’s is the second pill to show effectiveness against Covid-19, and it is the first purpose-built to attack the virus that causes the disease.
Pfizer’s is the second pill to show effectiveness against Covid-19, and it is the first purpose-built to attack the virus that causes the disease.
Pfizer’s is the second pill to show effectiveness against Covid-19, and it is the first purpose-built to attack the virus that causes the disease.
Experts strongly agree that the shots benefit the mother as well as the fetus.
La FDA podría autorizar dosis de refuerzo de vacunas diferentes de los que los estadounidenses recibieron en sus primeras dosis. Hay evidencia científica prometedora que […]
La FDA podría autorizar dosis de refuerzo de vacunas diferentes de los que los estadounidenses recibieron en sus primeras dosis. Hay evidencia científica prometedora que […]
Experts strongly agree that the shots benefit the mother as well as the fetus.
Experts strongly agree that the shots benefit the mother as well as the fetus.
The F.D.A. may authorize booster shots of vaccines different from the ones that Americans originally received. The science behind the move is promising.
The F.D.A. may authorize booster shots of vaccines different from the ones that Americans originally received. The science behind the move is promising.
Independent experts, including government scientists, were skeptical of the research from Israel, which included limited data over a short period.
Independent experts, including government scientists, were skeptical of the research from Israel, which included limited data over a short period.
Independent experts, including government scientists, were skeptical of the research from Israel, which included limited data over a short period.
A top White House adviser said monoclonal antibody treatments, sometimes underused, could still be crucial in helping people with Covid-19 avoid getting very sick.
A top White House adviser said monoclonal antibody treatments, sometimes underused, could still be crucial in helping people with Covid-19 avoid getting very sick.
A diagnostic test to detect long COVID could be available within six to 12 months, following the discovery that patients with the chronic condition have […]
France is handing out third shots of the two-dose vaccines to cancer patients and others with immune system impairments. In the United States, patients like […]
France is handing out third shots of the two-dose vaccines to cancer patients and others with immune system impairments. In the United States, patients like […]
Our Southeast Asia bureau chief breaks down the region’s pandemic reality.
The drug, from GlaxoSmithKline and Vir, aims to keep those who have contracted the disease out of the hospital.
The drug, from GlaxoSmithKline and Vir, aims to keep those who have contracted the disease out of the hospital.
The drug, from GlaxoSmithKline and Vir, aims to keep those who have contracted the disease out of the hospital.
The drug, from GlaxoSmithKline and Vir, aims to keep Covid patients out of the hospital.
Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help: monoclonal antibodies.
Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help: monoclonal antibodies.
Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help: monoclonal antibodies.
Una nueva formulación que está entrando en ensayos clínicos en Brasil, México, Tailandia y Vietnam podría cambiar la forma en que el mundo combate la […]
Una nueva formulación que está entrando en ensayos clínicos en Brasil, México, Tailandia y Vietnam podría cambiar la forma en que el mundo combate la […]
A new formulation entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic.
A new formulation entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic.
A new formulation entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic.
Shots: AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration The expanded collaboration will utilize […]
In an interview with PharmaShots, Brian Finrow, Co-Founder and CEO of Lumen Bioscience shared his views on the critical need for a scalable and cheaper […]
In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it […]
The government will pay $210 million for the doses, which Eli Lilly will ship by the end of March.
The government will pay $210 million for the doses, which Eli Lilly will ship by the end of March.
The government will pay $210 million for the doses, which Eli Lilly will ship by the end of March.
Researchers hope Eli Lilly’s new combination therapy will be better able to fight virus variants than a similar treatment already in use.
Researchers hope Eli Lilly’s new combination therapy will be better able to fight virus variants than a similar treatment already in use.
Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
Here’s information about who these therapies can help, how much they cost and how to find out if you can get them where you live.
While such treatments are promising, their use has been slowed by testing lags, overwhelmed hospitals and a perception the therapies are only for well-connected people.
While such treatments are promising, their use has been slowed by testing lags, overwhelmed hospitals and a perception the therapies are only for well-connected people.
While such treatments are promising, their use has been slowed by testing lags, overwhelmed hospitals and a perception the therapies are only for well-connected people.
Here’s information about who these therapies can help, how much they cost and how to find out if you can get them where you live.
Here’s information about who these therapies can help, how much they cost and how to find out if you can get them where you live.
Rudy Giuliani got monoclonal antibodies. You probably can’t.
Rudy Giuliani got monoclonal antibodies. You probably can’t.
Rudolph W. Giuliani became the latest in President Trump’s inner circle to boast about the treatment he received for Covid-19, as hospitals across the country […]
The treatment, made by the biotech company Regeneron, is a cocktail of two powerful antibodies that have shown promise for people who get it early […]
Chemotherapy has been a powerful method for fighting cancer for decades. One of the most effective therapies available, it is also known for weakening the […]
Shots: Qiagen reports the launch of the Access Anti-SARS-CoV-2 Total test that runs on a portable device and provides accurate results on Total Ig Abs […]
News from innovative healthcare startups from Specifica, Aerovate Therapeutics and more.
Copyright © 2024 | WordPress Theme by MH Themes